Thus, these findings indicate that the AMPA receptor-mediated activation of serotonergic systems may be involved in the antidepressant effect of ketamine. Among the glutamate receptors, the metabotropic glutamate 5 (mGlu5) receptor has been inhibitors reported to have roles in depression. Indeed, mGlu5 receptor levels are reportedly decreased in certain brain regions of depressed patients

and rodent models of depression (12), (13) and (14). In addition, mGlu5 receptor antagonists, such as 2-methyl-6-(phenylethynyl)-pyridine (MPEP), 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP), and (4-difluoromethoxy-3-(pyridine-2-ylethynyl)phenyl)5H-pyrrolo[3,4-b]pyridine-6(7H)-yl methanone (GRN-529), reportedly Inhibitor Library exhibited antidepressant effects in several animal models of depression (15), (16), (17) and (18), raising the possibility that mGlu5 receptor blockade may be a useful approach for treating depression. The neural mechanisms underlying the antidepressant effects of mGlu5 receptor antagonists have not been fully elucidated, although interactions with NMDA receptor and BDNF signaling have been suggested (for a review, see Ref. (19)). Recently, the involvement of serotonergic systems in the antidepressant and anxiolytic

effects of mGlu5 receptor antagonists has been reported. The antidepressant effect of MTEP was blocked by pretreatment with a tryptophan hydroxylase Fossariinae inhibitor, para-chlorophenylalanine (PCPA), in the tail http://www.selleckchem.com/products/dorsomorphin-2hcl.html suspension test (TST) (20), and both the antidepressant and anxiolytic effects of MTEP were also blocked by a 5-HT2A/2C receptor antagonist (20) and (21). Additionally, MTEP increased the extracellular 5-HT levels in the prefrontal cortex in rats (21). Thus, the antidepressant effect of mGlu5 receptor antagonists may mediate an increase in serotonergic systems, as observed for ketamine.

We recently reported that an mGlu5 receptor antagonist exhibited both acute and sustained effects in the NSF test (22), a model which measures latency to feed in an aversive environment and is sensitive to chronic but not acute treatment with antidepressants, and acute and sustained effects were also observed with ketamine (23). Using this model, we investigated the roles of the serotonergic system in the action of ketamine, as described above. Therefore, the NSF test is likely to be a useful model for comparing the neural mechanisms of an mGlu5 receptor antagonist, particularly the roles of the serotonergic system, with those of ketamine. However, the involvement of the serotonergic system in the action of an mGlu5 receptor antagonist in the NSF test has not been investigated.